Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04702802
Other study ID # SOPH149-0220/I
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 7, 2021
Est. completion date October 29, 2021

Study information

Verified date January 2021
Source Laboratorios Sophia S.A de C.V.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pilot, controlled, parallel group, open, randomized clinical trial to evaluate the safety of the viscoelastic substance PRO-149 (sodium hyaluronate 3%) after trans-surgical administration as a device in performing phacoemulsification and intraocular lens implantation in 36 patients with age-related cataract, compared to Healon® EndoCoat (sodium hyaluronate 3%).


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date October 29, 2021
Est. primary completion date October 29, 2021
Accepts healthy volunteers No
Gender All
Age group 49 Years and older
Eligibility Inclusion Criteria: - Age = 49 years old - Age-related cataract diagnosis which requires phacoemulsification and monofocal intraocular lens implantation - Being capable of voluntarily grant a signed informed consent. - Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures. - Willingness to be subjected to phacoemulsification and monofocal intraocular lens implantation. - An anterior chamber depth of = 2.8 mm measured through IOL Master®. - Pre-surgical cardiologic evaluation that validates the patient's eligibility to surgical procedure, including supporting studies: blood biometry, blood chemistry, clotting time, and electrocardiogram. This evaluation must not exceed 45 days prior to the date of signing of the informed consent. Exclusion Criteria: - Previous history of any systemic medical affliction that prevents a patient from being considered eligible for the surgical procedure under sedation and topical anesthesia. - Previous history of Diabetes Mellitus with A1C = 6.5% (48 mmol/mol) or glucose levels (after no caloric ingestion for = 8 hours) of = 126 mg/dL (7.0 mmol/L). - Poorly controlled systemic arterial hypertension, defined as a value = 140/90 despite the use of three antihypertensive drugs (one of them a diuretic) at maximum dose. - Previous history of ocular diseases that may limit the BCVA, or that may reactivate or worsen due to the surgical procedure or due to the use of topical steroids (por example, retinal detachment, macular degeneration, degenerative myopia, proliferative diabetic retinopathy, diabetic macular edema, optic neuritis, uveitis or any other kind of ocular inflammation, glaucoma, intraocular hypertension, corneal dystrophies or ectasias, history of ocular herpes or zoster). - Active ocular infection - Pseudoexfoliation syndrome in the eye to withstand surgery, or any other such zonular compromise. - Pharmacological mydriasis < 6 mm. - Any congenital anomalies in the eye to withstand surgery. - Any alteration that prevents a reliable Goldmann tonometry in the eye to withstand surgery. - IOP >21mmHg in the eye to withstand surgery, or previous history of IOP > 21 mmHg after topical steroid use. - Corneal endothelial cell count < 1500 cells/mm2 in the eye to withstand surgery. - Previous history of corneal or intraocular surgery. - Planned multiple procedures during cataract surgery (for example, trabeculectomy, keratotomies, etc) - Previous history of ocular trauma in the eye to withstand surgery (including surgical procedures) - Having one functional eye. - Having participated in clinical trials within 30 days prior to signing this study's informed consent form. - Having participated previously in this study. - Previous history of drug addiction within the last 2 years prior to signing this study's informed consent form. - Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date. - Having any kind of programed surgery during the period of this study. - Being or having any immediate family members (spouse, parent/legal tutor, sibling or child) who work either in the investigation center or for the sponsor of this study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Sodium hyaluronate 3%
During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
Sodium hyaluronate 3%
During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.

Locations

Country Name City State
Mexico SalaUno Salud, S.A.P.I. de C.V. Ciudad de mexico

Sponsors (1)

Lead Sponsor Collaborator
Laboratorios Sophia S.A de C.V.

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Other Trans-surgical evaluation During the phacoemulsification and intraocular lens implantation, the surgeon will evaluate the performance of the viscoelastic substance used during the procedure trough a questionnaire that will inquire on the following: Capability to maintain a formed anterior chamber during continuous circular capsulorhexis and intraocular lens implantation, retention during phacoemulsification, user-friendliness, ergonomics, ease of use during capsulorhexis, transparency during surgery and ease of use during extraction. Scale: 0 (very bad), 1 (bad), 2 (acceptable), 3 (good), 4 (very good). Days: 0 (surgery)
Primary Change in corneal endothelial cell count By means of specular microscopy, endothelial cell count will take place. Density expressed in cells/mm2 will be recorded. Normal density varies according to age, but an average of 1500 - 3500 cells/mm2 (age 40 to 90) has been described. Days: -15 (±2) (eligibility visit), and 29 (±2) (final visit)
Primary Change in intraocular Pressure (IOP) Measured through Goldman tonometer in milligrams of mercury (mmHg). After instillation of topical anesthetic (tetracaine 0.5%) and fluorescein stain, IOP is evaluated twice to obtain an average to be recorded. Normal values are considered between 10 and 21 mmHg. Days: -15 (±2) (eligibility visit), 1 (first safety evaluation visit), 8 (±2) (second safety evaluation visit), and 29 (±2) (final visit)
Secondary Incidence of adverse events Presence/absence adverse events, defined as the appearance of any unfavorable reaction in a patient participating in a clinical investigation in which any pharmaceutical product is being administered, regardless of the causal attribution. Days: -15 (±2) (eligibility visit), -8 (±3) (surgery scheduling visit), 0 (surgery), 1 (first safety evaluation visit), 8 (±2) (second safety evaluation visit), and 29 (±2) (final visit)
Secondary Change in central corneal thickness By means of specular microscopy, corneal thickness will be evaluated. Days: -15 (±2) (eligibility visit), and 29 (±2) (final visit)
Secondary Change in anterior chamber cellularity During evaluation with a slit lamp, setting the beam of light to 0.2 mm x 0.2 mm dimensions, it will be obliquely aimed to the anterior chamber. The standardized scale for anterior chamber cellularity (uveitis) will be used, according to number of observed cells: 0 (none), ½+ (1-5), 1+ (6-15), 2+ (16-25), 3+ (26-60), 4+ (>60). Days: -15 (±2) (eligibility visit), 1 (first safety evaluation visit), 8 (±2) (second safety evaluation visit), and 29 (±2) (final visit)
Secondary Change in anterior chamber flare During evaluation with a slit lamp, setting the beam of light to 0.2 mm x 0.2 mm dimensions, it will be obliquely aimed to the anterior chamber. The standardized scale for anterior chamber cellularity (uveitis) will be used: 0 (No flare), 1+ (Mild), 2+ (Moderate; iris and lens clearly visible), 3+ (Marked; slightly blurry iris and lens), 4+ (>60 cells; fibrin) Days: -15 (±2) (eligibility visit), 1 (first safety evaluation visit), 8 (±2) (second safety evaluation visit), and 29 (±2) (final visit)
Secondary Change in Best Corrected Visual Acuity (BCVA) With the patient's best possible refractive correction, visual acuity will be evaluated through the Snellen chart. Its notation (fraction or decimal) is described as the distance from the chart at which the test is performed, divided by the distance at which a letter equals vertically 5 minutes of arc. Days: -15 (±2) (eligibility visit), 1 (first safety evaluation visit), 8 (±2) (second safety evaluation visit), and 29 (±2) (final visit)
See also
  Status Clinical Trial Phase
Recruiting NCT05802550 - Metabo-lipidomics of the Ocular Surface for Cataract Surgery N/A
Recruiting NCT04246346 - Effectiveness of Using Interactive Consulting System to Enhance Informed Choice N/A
Recruiting NCT03340389 - Dysfunctional Lens Index Serves as a Novel Surgery Decision Maker for Age-related Cataracts N/A
Recruiting NCT04050644 - Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery Phase 4
Not yet recruiting NCT05028530 - Correlation Analysis of Lens Nucleus Density and Surgical Parameters Based on Ss-oct and Scheimpflug Technology
Completed NCT05573529 - EDOF and Multifocal IOL Study N/A
Recruiting NCT04711395 - The Application of Lens Dysfunction Index (DLI) in the Timing of Age-related Cataract Surgery
Completed NCT04262596 - Effectiveness of an Interactive Consulting System to Enhance Patients' Decision-making: A Randomized Controlled Trial N/A
Recruiting NCT02817191 - Effects of Holy-Comod and Tears Naturale Forte in Patients After Phaco+IOL N/A
Completed NCT05148741 - Evaluation of Capsular Bag Shape Changes After Plate-haptic Intraocular Lens Implantation by SS-OCT
Completed NCT06266962 - Comparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome Phase 4
Active, not recruiting NCT03992807 - A Decision Aid for Patients With Age-related Cataract N/A
Recruiting NCT05255796 - IOL-capsular Complex After Different Intraocular Lenses Implantation in Patients With High Myopia N/A
Recruiting NCT04443101 - Effective Lens Position After Cataract Surgery
Completed NCT04187157 - Association Between Light Spectrum and Survival After Cataract Surgery
Withdrawn NCT04163926 - Optometric Follow-up After Cataract Surgery N/A